Italia markets closed

OPKO Health, Inc. (0KCS.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,2096+0,1400 (+13,09%)
Alla chiusura: 07:13PM GMT
Schermo intero
Chiusura precedente1,0696
Aperto1,0700
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,0700 - 1,2500
Intervallo di 52 settimane0,8516 - 2,2315
Volume509.297
Media Volume114.049
Capitalizzazione5,735M
Beta (5 anni mensile)1,80
Rapporto PE (ttm)N/D
EPS (ttm)-0,1790
Prossima data utili01 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

    Provides Initial $59 Million and up to $168 Million Contingent on MilestonesNATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to advance a platform and specific candidates designed to address a range of p

  • GlobeNewswire

    Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

    JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology. It is challenging to administer peptides or

  • GlobeNewswire

    OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results

    Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA approved NGENLA™ for pediatric growth hormone deficiency; OPKO earned a $90 million milestone payment from its commercial partner, Pfizer. In June 2023, the U.S. Food and Drug Administration (FDA) approved